September 17, 2019 8:35am

As futures are pointing to another lower open

Monday, we were a safe haven as equities closed with a positive Advance/Decline (A/D) line of 32/11 versus Friday’s 18/22

News: CRISPR Therapeutics (CRSP +$2.00 at close), and ViaCyte, Inc., a privately-held cell therapy company, presented data from type 1 diabetes (T1D) program in an oral presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. The data demonstrate that the CyT49 pluripotent stem cell line, which has been shown to be amenable to efficient scaling and differentiation, can be successfully edited with CRISPR. The CyT49 pluripotent stem cell line is currently being used to generate islet progenitors for clinical trials.

My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future

 

Timely insights have line extensions within or to a volatile pricing universe. Thus my line in writing is separating actionable numbers or intelligence and news into a short-term investment thesis to tackle the “unknown unknowns”

 

Dow futures are DOWN -0.21% (-458 points), S&P futures are DOWN -0.13% (-4 points) and NASDAQ futures are also DOWN -0.09% (-7 points)

 

Futures have come off their lows, markets are still endangered by oil pricing rising (+$10.00 per barrel) after drone attack forced Saudis to cut output in half;

European stocks slipped lower as investors monitor the fallout from the weekend’s Saudi oil attacks. The pan-European Stoxx 600 was down 0.2% by mid-morning, basic resources stocks shedding 2% while shares of oil and gas companies continued to climb, adding a further 0.6% amid the escalating tensions in the Middle East;

Asia Pacific markets traded mixed as investor sentiment turned cautious over rising energy prices and heightened geo-political tensions.

 

Data docket: new business leaders survey, due at 8:30 a.m. ET; industrial production numbers will be out at 9:15 a.m.; and the housing market index due at 10 a.m. ET.

 

Henry’omics:

Let’s NOT over-react to the Saudi oil attacks; the U.S. central bank has traditionally described moves in the volatile oil markets as ... inputs that central bankers tend to view as ... temporary.

Investors are starting to shift their focus to an upcoming Federal Reserve meeting. There’s uncertainty among market players about what the central bank will do. The recent increase in energy prices led some investors to believe that the Fed isn’t in such a hurry to cut rates <CNBC>.

 

Never forget ... who were some or most  the pilots behind the 9/11 historical disaster and deaths to Americans! Let them fight their own battles!

 

From Monday’s evening post, “yippie-yi-yo-kai-yay; the cell and gene therapy sector was a safe haven in today’s market. Keep it that way, we NEED read-outs of positive clinical data; another I told you so, Adverum (ADVM +$0.51) would pop!”

•             The NASDAQ was down -23.15 or -0.28% to 8,153.54;

•             The IBB closed up +0.94% while the XBI also closed up +1.44%

•             The close was positive with an Advance/Decline (A/D) line of 31/11 and 1 flat and 2 acquired;

•             The range of the 32 upside was +0.03% (ONCE) to +8.82% (ADVM) while the 11 downside ranged from -0.23% (PSTI) to -5.26% (CLBS);

•             6 out of the 32 upside had higher than the 3 month average volume;

•             3 out of the 11 downside had higher than the 3 month average volume;

Q3/19 to date:

  • In July, there were 9 positive, 1 holiday and 13 negative closes;
  • In August there had been 12 negative and 10 positive closes
  • In September there has been 6 positive, 1 holiday and 4 negative close

 

Companies in my headlights – It’s your decision; I provide an idea and context:

*** What will be ‘will be but, I’d be cautious – let the machines and algorithms do their best or worst for entering this sector …

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.